Myelofibrosis Excellence Forum

Myelofibrosis

Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Q&As

Evaluating the Correlation Between Anemia and Blast Phase Evolution Risk Among Patients With Myelofibrosis

02/21/2024

Francesca Palandri, MD, PhD, evaluates the correlation between anemia and an increased risk of evolution into blast phase for patients with ruxolitinib-treated myelofibrosis.

Francesca Palandri, MD, PhD,...

02/21/2024

Oncology

Videos

Mitigating Potential Treatment Risks Among Patients With Myelofibrosis

02/02/2024

Aaron Gerds , MD;

Aaron Gerds, MD, examines potential treatment risks for patients with myelofibrosis and how to mitigate them in order to achieve the best possible outcomes.

Aaron Gerds, MD, examines...

02/02/2024

Oncology

Videos

Exploring the Benefits of Momelotinib for Patients With Myelofibrosis, Including With Anemia

02/02/2024

Aaron Gerds , MD;

Aaron Gerds, MD, discusses the phase 3 MOMENTUM trial on momelotinib treatment for patients with myelofibrosis, including those with anemia, which served as the basis for the approval of momelotinib by the US FDA.

Aaron Gerds, MD, discusses the...

02/02/2024

Oncology

Conference Coverage

Examining Predictors of Emergent Thrombocytopenia After Ruxolitinib Treatment Among Patients With Myelofibrosis

01/03/2024

Douglas Tremblay , MD;

At the 2023 ASH Annual Meeting, Douglas Tremblay, MD, discussed the prevalence and predictors of emergent thrombocytopenia following ruxolitinib treatment among patients with myelofibrosis.

At the 2023 ASH Annual Meeting,...

01/03/2024

Oncology

Claire Harrison, MD, FRCP, Guy’s and St. Thomas’ NHS Foundation Trust

Conference Coverage

Ruxolitinib Therapy Demonstrates Reduced JAK2 Allele Burden and Improvement in Hematocrit Control and Symptom Burden for Patients With PV

12/21/2023

Claire Harrison , MD;

At the 65th ASH Annual Meeting in San Diego, California, Claire Harrison, MD, FRCP discussed a pooled efficacy analysis that provided further evidence of the benefit of ruxolitinib treatment for patients with polycythemia vera, with or...

At the 65th ASH Annual Meeting...

12/21/2023

Oncology

Pankit Vachhani, MD, O’Neal Comprehensive Cancer Center

Conference Coverage

Platelet Count Response Among Patients With Cytopenic Myelofibrosis Treated With Pacritinib

12/21/2023

Pankit Vachhani , MD;

At the 65th ASH Annual Meeting in San Diego, California, Pankit Vachhani, MD, presented data that platelet count improvement occurred in a subset of patients with myelofibrosis treated with pacritinib.

At the 65th ASH Annual Meeting...

12/21/2023

Oncology

Ruben A. Mesa, MD, FACP, Atrium Health Wake Forest Baptist Comprehensive Cancer Center

Videos

Novel Advances in the Treatment of Patients With Myelofibrosis

11/07/2023

Ruben A. Mesa , MD, FACP;

At the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, Ruben A. Mesa, MD, FACP, discusses the latest updates in myelofibrosis treatment.

At the 2023 Lymphoma, Leukemia &...

11/07/2023

Lymphoma, Leukemia & Myeloma Network

Videos

Recent Advancements in Clinical Development for the Treatment of Myelofibrosis

05/04/2023

At the 2023 Great Debates & Updates in Hematologic Malignancies conference, New York, John Mascarenhas, MD, discussed recent advancements in clinical developments for the treatment of myeloproliferative neoplasms, specifically myelofibrosis,...

At the 2023 Great Debates &...

05/04/2023

Oncology

Videos

Momelotinib Demonstrates Consistent Long-Term Safety in Patients With Myelofibrosis

01/19/2023

Srdan Verstovsek, MD, discusses the long-term safety of momelotinib in patients with high- and intermediate-risk myelofibrosis, using data from 3 randomized controlled trials: SIMPLIFY-1, SIMPLIFY-2, and MOMENTUM.

Srdan Verstovsek, MD, discusses...

01/19/2023

Oncology

Videos

Ruxolitinib in Patients With Myelofibrosis Who Had Anemia or Thrombocytopenia: Real-World Outcomes

12/20/2022

Srdan Verstovsek, MD, presents data on real-world outcomes of the use of ruxolitinib in patients with myelofibrosis who had anemia or thrombocytopenia at the ASH 2022 Meeting in New Orleans, LA.

Srdan Verstovsek, MD, presents...

12/20/2022

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology